Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company, introducing GRAFAPEX (treosulfan) for Injection which is the first and only FDA-approved conditioning regimen, that is indicated for use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients one year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).